Precision medicine based on matabolic pathways in lung cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09229
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Keio University
• Principal Investigator: Soejima Kenzo 慶應義塾大学, 医学部(信濃町), 教授 (30236145)
• Co-Investigator(Kenkyū-buntansha): 浜本 純子 慶應義塾大学, 医学部(信濃町), 特任助教 (40570239) ; 安田 浩之 慶應義塾大学, 医学部(信濃町), 講師 (70365261)
• Co-Investigator(Renkei-kenkyūsha): HISHIKI Takako 慶應義塾大学, 医学部, 講師 (10338022)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: がん代謝 / メタボローム解析 / 肺がん / Imaging MS / 高濃度酸素暴露 / Bevacizumab / Nintedanib / AMPK

Outline of Final Research Achievements

Comprehensive analysis of metabolic pattern in lung cancer tissues and normal tissues using capillary electrophoresis-mass spectrometry (CE-MS) and imaging MS revealed that metabolites derived from glycolysis such as lactate, nucleic acid metabolites and branched chain amino acids were increased in the cancer tissues compared to the normal counterparts. Visualization of metabolites distribution by imaging MS revealed that 2 different kind of anti-angiogenic inhibitors, namely bevacizumab and nintedanib demonstrated distinct metabolic patterns despite both showed potent anti-tumor effect. We also identified anti-tumor effect of hyperoxia in lung cancer cell lines via activation of AMPK pathway, suggesting the possibility of clinical application of exposure to hyperoxia in lung cancer patients.

Free Research Field

臨床腫瘍学